Pāriet uz galveno navigāciju Pāriet uz meklēšanu Pāriet uz galveno saturu

The Role of Nutraceuticals in Statin Intolerant Patients

  • International Lipid Expert Panel (ILEP)
  • Medical University of Łódź
  • University of Zielona Gora
  • University of Palermo
  • University of Bologna
  • Institute of Genetics and Animal Breeding of the Polish Academy of Sciences
  • University of Vienna
  • University of Prishtina “Hasan Prishtina”
  • Sorbonne Université
  • Université catholique de Louvain
  • University of Belgrade
  • RAS - USSR Cardiology Research Center
  • University Medical Centre
  • University of Göttingen
  • Aristotle University of Thessaloniki
  • General Hospital St. Jan
  • University of British Columbia
  • University College London
  • National Scientific Center M.D. Strazhesko Institute of Cardiology
  • University of Kansas
  • University of Alabama at Birmingham
  • Harokopio University
  • University of Debrecen
  • Paracelsus Private Medical University
  • P. J. Safarik University
  • National and Kapodistrian University of Athens
  • University of Zagreb
  • St George's University Hospitals NHS Foundation Trust
  • IRCCS San Raffaele Pisana - Roma
  • Icahn School of Medicine at Mount Sinai
  • Mashhad University of Medical Sciences
  • Victor Babes University of Medicine and Pharmacy
  • Carol Davila University of Medicine and Pharmacy
  • Charles University
  • Royal Perth Hospital
  • University of California at Irvine

Zinātniskās darbības rezultāts: Devums žurnālamPārskata rakstskoleģiāli recenzēts

244 Atsauces (Scopus)

Kopsavilkums

Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non–lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction.

OriģinālvalodaAngļu
Lapas (no-līdz)96-118
Lapu skaits23
ŽurnālsJournal of the American College of Cardiology
Sējums72
Izdevuma numurs1
DOIs
Publikācijas statussPublicēts - 3 jūl. 2018

ANO IAM

Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

  1. 3. IAM — Laba Veselība un Labbūtība
    3. IAM — Laba Veselība un Labbūtība

Nospiedums

Uzziniet vairāk par pētniecības tēmām “The Role of Nutraceuticals in Statin Intolerant Patients”. Kopā tie veido unikālu nospiedumu.

Citēt šo